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Abstract
We sought to benchmark the quality of HIV care being received by persons living with HIV in
care in Washington, DC and identify individual-level and structural-level differences. Data
from the DC Cohort, an observational HIV cohort of persons receiving outpatient care in DC,
were used to estimate the Institute of Medicine (IOM) and Department of Health and Human
Services (HHS) quality of care measures. Differences in care by demographics and clinic
type were assessed using χ2 tests and multivariable regression models. Among 8,047 par-
ticipants, by HHS standards, 69% of participants were retained in care (RIC), 95% were
prescribed antiretroviral therapy (ART), and 84% were virally suppressed (VS). By IOM
standards, 84% were in continuous care; and 78% and 80% underwent regular CD4 and VL
monitoring, respectively. Screening for syphilis, chlamydia, and gonorrhea was 51%, 31%,
and 26%, respectively. Older participants were 1.5 times more likely to be RIC compared to
younger participants (OR: 1.5; 95% CI: 1.3, 1.8). Participants enrolled in community-based
clinics were more likely to be RIC (OR: 1.7; 95% CI: 1.4, 2.0) versus those enrolled at hospi-
tal-based clinics. Older participants were more likely to achieve VS than younger partici-
pants (OR: 1.8; 95% CI: 1.5, 2.2) while Black participants were less likely compared to white
participants (OR: 0.4; 95% CI: 0.3, 0.5). Despite high measures of quality of care, disparities
remain. Continued monitoring of the quality of HIV care and treatment can inform the devel-
opment of public health programs and interventions to optimize care delivery.
Introduction
The US National HIV/AIDS Strategy has established specific targets for persons living with
HIV/AIDS (PLWHA) which include having 90% of people living with HIV diagnosed, 90%
retained in HIV medical care, 80% achieving viral suppression, and ensuring 95% of PLWHA
have stable housing [1]. In order to measure progress in achieving those targets, established
HIV clinical cohorts and federally-funded HIV/AIDS programs are able to measure the quality
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of HIV clinical care along the HIV care continuum, a widely-adopted public health framework
summarizing sequential steps from HIV diagnosis to optimal care resulting in viral suppres-
sion [2–4]. Clinical cohorts such as the North American AIDS Cohort Collaboration (NA-AC-
CORD), as well as local and national HIV surveillance registries, use a set of core indicators
including those developed by the Institute of Medicine (IOM) and the Department of Health
and Human Services (HHS), to track and compare the delivery of care within and across
other, similar populations of PLWHA [5–8].
In Washington, DC- a city with a 2.5% HIV prevalence- the measurement and assessment
of care delivery at a population-level is facilitated by a unique study, the DC Cohort study. The
DC Cohort is a longitudinal, observational study of PLWHA receiving HIV care at 13 of the
large publicly-funded, government, and academic medical center clinics in Washington, DC
[9]. The DC Cohort, which provides representative data on PLWHA persons living with HIV
in DC, follows participants receiving outpatient HIV/AIDS care by combining their clinical
data into a centralized database. Given the study’s unique ability to aggregate data and capture
care delivery at a diverse set of HIV clinics in a highly impacted area, the Cohort has been
identified as a comprehensive data source to monitor HIV care in DC [10].
Consistent with the overarching goals of the DC Cohort and in support of the Affordable
Care Act (ACA) that prioritizes the delivery and tracking of high-quality patient care, the
objectives of this study were to: 1) benchmark the quality of HIV care being delivered at DC
Cohort sites by applying HHS and IOM quality of care indicators for retention in HIV medical
care, antiretroviral therapy (ART use), HIV viral load (VL) suppression and other measures;
and 2) determine whether individual-level predictors such as age, sex, race/ethnicity, HIV
transmission risk and structural–level predictors such as clinic type influence quality of care
measures [11, 12].
Methods
Study population
The DC Cohort began enrollment in January 2011; 8,047 consenting PLWHA who receive
HIV care at one or more participating clinics, independent of DC residence status, were
enrolled as of September 30, 2016. Of the 13 DC Cohort sites, eight are hospital-based and five
are community-based clinics. Participants’ clinical data were abstracted from patient medical
records and entered into a web-based data entry system called Discovere1 (Cerner Corpora-
tion, Kansas City, MO). The study protocol, consent forms, and research instruments were
approved by the George Washington University Institutional Review Board (IRB), the DC
Department of Health (DOH) IRB, and the IRBs of Howard University, Georgetown Univer-
sity, Medstar Research Institute, and the Veterans Affairs Medical Center. Reliance agreements
with the GWU IRB were established with the remaining clinical sites. Details of the DC Cohort
study design have been described previously [10, 12, 13].
Outcomes
Among the HHS and IOM indicators, four out of seven HHS-defined indicators and seven out
of nine IOM-defined indicators were selected based on what could feasibly be measured using
existing data collected in the DC Cohort. Data were collected on participants enrolled as of
September 30, 2016 and reported to the DC Cohort as of December 15, 2016. Measures were
computed among those who had12 months of follow-up, with the exception of the HHS
indicator on retention-in-care which required24 months of follow-up [2, 4]. For measures
requiring care visits within a specified interval of time, in addition to documented clinical
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encounters, CD4 or VL test results served as proxies for HIV primary care encounters, a stan-
dard practice used by HIV cohorts and surveillance programs [14–17].
In 2012, HHS developed a set of common, core measures to estimate outcomes along the
HIV care continuum as part of a larger initiative to strengthen the federal response to HIV/
AIDS through planning and evaluating domestic HIV/AIDS programs within and across agen-
cies. Based on an assessment of federally-funded HIV prevention, treatment, and care services,
HHS identified core indicators related to continuous HIV clinical care and access to support-
ive services. Selected core indicators were measured, including retention in care, ART use,
viral load suppression, and housing status (Table 1) [2]. Similarly, the IOM has also developed
a set of core indicators related to continuous HIV clinical care as part of an initiative to moni-
tor the effect of both the National HIV/AIDS Policy and ACA on improving HIV care [1, 11].
Select core indicators were measured, including continuous care, regular CD4 and viral moni-
toring, maintenance of immune function, and screening for chlamydia, gonorrhea, and syphi-
lis (Table 1) [4].
Statistical analyses
Frequencies on demographic and clinical characteristics at study enrollment (‘baseline’) were
computed. HIV-related clinical characteristics such as history of AIDS, baseline CD4 and VL
Table 1. HHS and IOM quality of care indicators assessed using DC Cohort study dataa.
HHS Measure HHS definition IOM measure IOM definition
Retention-in-care Proportion of HIV+ persons who had1 HIV
medical care visit in each 6-month period of
the 24 month measurement period, with60
days between the first medical visit in the prior
6 month period and the last medical visit in the
subsequent 6-month period among those with
24 months of follow-up
Proportion in continuous HIV
care
Proportion of HIV+ people who had2
routine HIV medical care visits or a CD4 or
viral load test in the preceding 12 months 3
months apart among those with12 months
follow-up
ARV therapy among
persons in HIV
medical care
Proportion of HIV+ persons who are
prescribed ART in the 12-month measurement
period among those with12 months follow-
up and1 visit
Regular CD4 testing for
monitoring immune function
Proportion of HIV+ people who received2
CD4 tests in 12 months since enrollment
among those with12 months follow-up
Viral load (VL)
suppression among
persons in care
Proportion of HIV+ persons with a viral load
<200 copies/ml at last test in the 12–month
measurement period among those with12
months follow-up and 1 visit and 1 VL
Regular VL monitoring for
clinical progression
Proportion of HIV+ people receiving2 VL
tests in 12 months since enrollment among
those with12 months follow-up
Housing instability Proportion of HIV+ persons who were
homeless or unstably housed in the 12-month
measurement period among those with12
months follow-up with housing information
recorded
Maintenance of immune
function to reduce risk of
opportunistic infections and
cancer
Proportion of HIV+ people in continuous care
for12 months and with a CD4+ cell count
350 cells/mm3 among those in continuous
care for 12 months
Screening for Gonorrhea Proportion of HIV+ people who were
screened for Gonorrhea1 since enrollment
among those with12 months follow-up
Screening for Chlamydia Proportion of HIV+ people who were
screened Chlamydia1 since enrollment
among those with12 months follow-up
Screening for Syphilis Proportion of HIV+ people who were
screened for Syphilis1 since enrollment
among those with12 months follow-up
aIOM = Institute of Medicine; HHS = Department of Health and Human Services.
https://doi.org/10.1371/journal.pone.0186036.t001
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results (defined as the closest lab result reported within six months prior and 30 days after
enrollment), ART exposure status and regimen type (among those prescribed ART) were also
measured. HHS and IOM indicators were computed and chi-square test statistics were used to
determine differences in six selected indicators by demographic and clinical characteristics.
Multivariable logistic regression models were used to estimate adjusted odds ratios (OR) and
95% confidence intervals (CI); models included age, sex at birth, race/ethnicity, HIV transmis-
sion risk group and clinic type (hospital versus community-based). Bonferroni correction was
applied to account for multiple testing; p-values <0.0083 (i.e., 0.05/6) were considered as the
threshold for statistical significance. All analyses were completed using SAS version 9.4 (SAS
Institute, Cary, NC).
Results
Participant characteristics
Among the 8,047 participants enrolled by September 2016, 91% and 62% had at least 12 and
24 months of follow up, respectively. The proportion of participants who were non-Hispanic
black was 78% and the median age was 47 years. Most were publically insured (63%); more
than half were receiving HIV care at community-based clinics (53%) and 75% were DC resi-
dents (Table 2). The most common mode of HIV transmission was men who had sex with
men (MSM; 39%), followed by heterosexual risk (32%).
At enrollment, 52% of participants had a CD4 count above 500 cells/μl, and 42% of partici-
pants had a history of AIDS. The proportion of treatment prescribed participants was 92% at
enrollment (Table 2). Seventy-three percent of participants had a VL at enrollment that was
less than 200 copies/ml.
Indicator measurement
For HHS-defined indicators, 69% of participants were retained in care, 95% had been pre-
scribed ART, and 84% were virally suppressed at the end of their first year of follow-up (Fig 1).
Although at enrollment, 8% of participants were homeless or temporarily housed, during the
follow up period, 11% of participants were unstably housed. For IOM-defined indicators, 84%
were in continuous care. The proportion of participants who received regular CD4 and VL
monitoring was 78% and 80%, respectively. Among those in continuous care, 81% achieved
and maintained immune function as measured by CD4 counts 350 cells/μl. The proportion
of participants screened for syphilis, chlamydia, and gonorrhea was 51%, 31%, and 26%,
respectively.
Comparison of indicators by participant demographics
Differences in crude proportions for HHS-defined indicators were observed by demographic
characteristics (Table 3). The proportion of participants retained in care was significantly
higher among older participants (47 versus <47), injection drug users and those with ‘other’
risks for HIV and those who enrolled at community-based DC Cohort sites (versus hospital-
based sites). After adjustment for sex, race/ethnicity, HIV risk group and clinic type, older par-
ticipants were 1.5 times more likely to be retained in care compared to younger participants
(OR: 1.5; 95% CI: 1.3, 1.8); those with ‘other’ HIV risk compared to MSM (OR: 2.8, 95%CI 1.8,
4.3); and those enrolled in community-based clinics were also more likely to be retained (OR:
1.7; 95% CI: 1.4, 2.0). The proportion of participants prescribed ARVs was significantly higher
among older participants and males (p-value<0.0083 for both); no differences were observed
by race, risk, or clinic type. After adjustment, older participants were more likely to be
Monitoring the quality of HIV care in DC
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Table 2. Demographic and clinical characteristics at enrollment, DC Cohort Study, Washington, DC
2011–2016a,b.
Analytic population
N %
Total 8,047 100
Age at enrollment
Median (IQR) 47.0 (36.3, 54.6)
Sex at birth
Female 2,209 27.5
Male 5,838 72.5
Race/ethnicity
Black 6,250 77.7
White 1,155 14.4
Other/Unknownb 642 8.0
Insurance
Private 2,076 25.8
Public 5,079 63.1
Other 158 2.0
Unknown 734 9.1
State of residence
DC 5,994 74.5
MD 1,494 18.6
VA 453 5.6
WV 34 0.4
Other/Unknown 72 0.9
Clinic type
Community-based 4,282 53.2
Hospital -based 3,765 46.8
Housing status
Permanent 5,228 65.0
Homeless/Temporary 630 7.8
Other/Unknown 2,189 27.2
HIV riskc
MSM 3,129 38.9
Heterosexual 2,588 32.2
IDU 541 6.7
Other 396 4.9
Unknown 1,393 17.3
AIDS diagnosis 3,403 42.3
CD4 count (cells/μl)
<50 223 2.8
50–199 663 8.2
200–499 2,752 34.2
500+ 4,182 52.0
Unknown 227 2.8
VL (copies/ml)
(Continued )
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prescribed ARVs in multivariable analyses (OR: 1.5; 95% CI: 1.1, 2.1). The proportion of par-
ticipants who were virally suppressed was significantly higher among older participants, males,
whites, and MSM. After adjustment, older participants were nearly two times more likely to
achieve viral suppression than their younger counterparts (OR: 1.8; 95% CI: 1.5, 2.2). In con-
trast, non-Hispanic blacks were 0.4 times less likely to achieve viral suppression compared
with non-Hispanic whites (OR: 0.4; 95% CI: 0.3, 0.5) and persons with ‘other’ transmission
risk were 0.5 times less likely than MSM (0R: 0.5; 95% CI: 0.3, 0.7); Table 3).
Differences in crude proportions for IOM-defined indicators were observed by demo-
graphic characteristics (Table 4). The proportion receiving regular CD4 monitoring was higher
among older participants, females, Blacks and those with ‘other’ risk. After adjustment, per-
sons identified as ‘other/unknown’ race were less likely and persons identified as ‘other’ risk
were more likely to undergo regular CD4 monitoring (OR: 0.6; 95% CI: 0.5, 0.9 and OR: 2.2;
95% CI: 1.4, 3.4, respectively). Significant differences were observed in regular VL monitoring
by sex, race, HIV risk, and clinic type. After adjustment, persons identified with ‘other’ risk
and those enrolled in community-based clinics were more likely to achieve VL monitoring
(OR: 2.1; 95% CI: 1.4, 3.4 and OR: 1.3; 95% CI: 1.1, 1.5, respectively). Differences in crude
Table 2. (Continued)
Analytic population
N %
<200
200–399
00–9,999
10,000–99,9999
100,000
Unknown
5,870
227
707
675
329
239
72.9
2.8
8.8
8.4
4.1
3.0
ARV status
Prescribed
ot prescribed
Unknown
7,424
542
81
92.3
6.7
1.0
ARV regimens among those prescribed (at enrollment)
PI-based 2,299 31.0
NNRTI-based 2,107 28.4
Dual class regimens 676 9.1
INSTI-based 966 13.0
NRTI only regimens 166 2.2
Triple class regimens 149 2.0
Other regimensd 8 0.1
No recorded ARV regimen at baseline 1,053 14.2
aIncludes enrolled participants who consented as of September 30, 2016. Data reported to the DC HIV
Cohort study as of December 15, 2016. Baseline demographic characteristics reflect data reported at study
enrollment.
bOther race includes races reported as Hispanic, Asian, American Indian/Native American, Hawaiian/Other
Pacific Islander, White-Black, and Other.
cMSM risk includes persons identified as having both MSM and injection drug use risk. Other risk includes
perinatal transmission (65%), transfusion/coagulation disorder (19%), hemophiliacs and risk due to
occupational exposure and other (16%).
dOther ARV regimens include TDF+FTC+MVC, 3TC+ABC+TDF+MVC, and AZT+TDF+FTC+MVC
Notes: IQR = interquartile range; NH = non-Hispanic; MSM = men who have sex with men; IDU = male or
female injection drug user. VL = viral load; ARV = antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0186036.t002
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proportions for maintenance of immune function were observed by sex, race, and HIV risk.
After adjustment, persons identified as ‘other/unknown’ race were 0.5 times less likely to
achieve maintenance of immune function compared to whites (OR: 0.5; 95% CI: 0.4, 0.8).
Discussion
Using aggregate data from a clinic-attending population of PLWHA, we were able to create a
comprehensive snapshot of a standard set of quality of care and HIV care continuum outcomes
among an urban population of PLWHA to identify areas of success, gaps, and disparities in care
outcomes. When comparing our HHS-defined retention-in-care estimate to other published
estimates, we found that retention among DC Cohort participants was slightly lower than par-
ticipants in NA-ACCORD (71–75%) but higher than that reported by the HIV Research Net-
work and others (59%-65%) [4, 14–21]. The DC Cohort IOM continuity of care estimate was
relatively high at 84% and higher than local surveillance estimates of 69%; however, this mea-
sure only relies on 12 months of follow-up [22]. Thus the IOM continuity of care measure may
be a better indicator for initial or short term engagement in care, whereas the HHS indicator
(which requires 24 months of observation) may be more useful for assessing longer-term fol-
low-up.
The HHS-defined prescribed ARV estimate of 95% was higher than both the NA-ACCORD
estimate of 82% and Veterans Aging Cohort Study (VACS) estimate of 91% [4, 23]. Similarly,
our HHS-defined viral suppression estimate of 84% exceeded the DC surveillance estimates
(57%), the Center for Disease Control’s National HIV Surveillance System estimate (48%), NA-
ACCORD estimates (54–78%) and other large cohort estimates (66–76%) [5, 6, 16, 19, 24–26].
Further analysis to examine the role of specific ART regimens and viral suppression may be war-
ranted to better characterize effective regimens among this population. With respect to routine
immunologic and virologic monitoring, our estimates for regular CD4 and VL monitoring of
78% and 80%, respectively, were similar to the VACS estimate of 80% [23, 24]. These relatively
high estimates indicate that patients enrolled in the DC Cohort are well engaged in HIV care.
Fig 1. Proportion of DC cohort participants meeting criteria for selected HHS and IOM indicators for quality of care, DC
cohort, 2011–2016. This figure represents individuals who were enrolled in the DC Cohort as of September 30, 2016 and met the
criteria for selected Department of Health and Human Services and Institute of Medicine HIV quality of care indicators. While high
proportions of participants met the HIV-related indicators (69%-95%), screening for sexually transmitted infections was relatively low
(26%-51%).
https://doi.org/10.1371/journal.pone.0186036.g001
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In contrast, our estimates for routine screening for STIs were much lower compared to our
higher rates of care continuity, ARV prescription, and viral suppression. The DC Cohort esti-
mate for routine screening of gonorrhea (NG) and chlamydia (CT) were lower than combined
testing estimates of NG/CT observed in other HIV clinical cohorts (26% and 31% versus 39–
42% in other cohorts) [27, 28]. Similarly, the DC Cohort screening estimate for syphilis was
lower than other HIV cohorts of persons in care (51% versus 65%) [28]. Given the recent
increases in syphilis, gonorrhea, and chlamydia rates observed among PLWHA, particularly
MSM, providers need to be reminded of the importance of secondary prevention and routine
sexually transmitted disease screening among PLWHA [27–31]. Further analyses by demo-
graphic and transmission risk characteristics are needed to identify sub-groups least likely to
be screened.
The disparities in care outcomes observed with regard to age, race, and housing have
previously been documented in this Cohort and in other HIV cohort analyses; with older
Table 3. Factors associated with select HHS-defined care indicators, DC Cohort, 2011–2016a,b,c.
Retention in care Prescribed ARV therapy Viral load suppression
N Row % P-value aOR
(95% CI)
N Row % P-value aOR
(95% CI)
N Row% P-value aOR
(95% CI)
Total 3,450 68.8 6,795 95.3 5,806 83.8
Age
<47 1,556 64.6 <0.0001 Ref 3,342 94.5 0.0013 Ref 2,740 80.0 <0.0001 Ref
47 1,894 72.6 1.5 (1.3, 1.8) 3,453 96.1 1.5 (1.1, 2.1) 3,066 87.7 1.8 (1.5, 2.2)
Sex at birth
Male 2,510 69.0 0.4885 Ref 4,960 95.8 0.0013 Ref 4,282 85.4 <0.0001 Ref
Female 940 68.0 0.9 (0.7, 1.2) 1,835 94.0 0.7 (0.4, 1.0) 1,524 79.8 0.9 (0.7, 1.1)
Race
Black 2,754 69.1 0.4198 1.0 (0.8, 1.3) 5,298 95.2 0.5918 1.0 (0.6, 1.5) 4,420 81.6 <0.0001 0.4 (0.3, 0.5)
White 481 68.1 Ref 989 95.8 Ref 921 93.0 Ref
Other/
Unknownd
215 65.8 0.9 (0.6, 1.4) 508 94.8 0.9 (0.4, 1.7) 465 89.4 0.7 (0.4, 1.2)
HIV Riske
MSM 1,290 67.5 <0.0001 Ref 2,641 95.4 0.0793 Ref 2,310 86.6 <0.0001 Ref
HRH 1,083 66.8 0.9 (0.7, 1.2) 2,197 94.9 1.1 (0.7, 1.7) 1,862 82.2 0.9 (0.7, 1.1)
IDU 297 76.0 1.3 (0.9,1.8) 461 93.5 0.6 (0.3, 1.1) 392 83.2 0.7 (0.5, 1.1)
Other 224 80.3 2.8 (1.8, 4.3) 337 94.9 1.2 (0.6, 2.6) 237 68.5 0.5 (0.3, 0.7)
Unknown 556 68.3 0.9 (0.7, 1.2) 1,159 96.5 1.4 (0.9, 2.4) 1,005 85.6 1.0 (0.7, 1.3)
Clinic Type
Hospital-based 1,495 63.8 <0.0001 Ref 3,190 95.3 0.8139 Ref 2,717 82.8 0.0203 Ref
Community-based 1,955 73.1 1.7 (1.4, 2.0) 3,605 95.2 1.0 (0.7, 1.3) 3,089 84.8 1.2 (1.0, 1.4)
aRow percent represents the proportion of participants who met the specific measure out of the population in each demographic group.
bP-value represents statistical differences by demographic characteristics; P-values less than 0.0083 are considered statistically significant, using a
Bonferroni correction for multiple testing.
cAdjusted odds ratio (aOR) are adjusted for all other variables presented in the table; aORs in bold denote statistical differences at the 0.0083 level, using a
Bonferroni correction for multiple testing.
dOther race includes races reported as Hispanic, Asian, American Indian/Native American, Hawaiian/Other Pacific Islander, White-Black, and Other.
eMSM risk includes persons identified as having both MSM and injection drug use risk. Other risk includes perinatal transmission (65%), transfusion/
coagulation disorder (19%), hemophiliacs and risk due to occupational exposure and other (16%).
Note. HHS = Health and Human Services; ARV = antiretroviral; OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; HRH = high
risk heterosexual risk; IDU = injection drug use; CBO = community-based organization
https://doi.org/10.1371/journal.pone.0186036.t003
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persons, whites, and those stably housed doing better than comparison populations [5, 32–
36]. Similarly, the observation that perinatally infected participants, who comprise 65% of
‘other’ HIV risk, had a higher likelihood of being retained but lower likelihood of achieving
viral suppression is consistent with previous Cohort findings and national trends [7, 32, 37].
Interestingly, we also observed differences by clinic type with participants at community-
based clinics having more regular VL monitoring and better retention in care than those
enrolled at hospital-based clinics. This observation differs from that of other studies that
did not find meaningful differences in retention with respect to clinic type [38, 39]. Further
exploration of patient characteristics by site, as well as characterization of care delivery such
as the receipt of primary care and availability of ancillary services at each site, as well as the
costs of providing these services, is necessary to fully understand the implications of these
findings.
Table 4. Factors associated with select IOM-defined care indicators, DC Cohort, 2011–2016a,b,c.
Regular CD4 monitoring Regular viral load monitoring Maintenance of immune function
N Rowa % P-valueb aORc
(95% CI)
N Rowa % P-valueb aORc
(95% CI)
N Row
%a
P-valueb aORc
(95% CI)
Total 5,744 78.1 5,873 79.9 5,024 81.3
Age
<47 2,799 76.7 0.0048 Ref 2,881 79.0 0.0633 Ref 2,460 82.0 0.2305 Ref
47 2,945 79.4 1.2 (1.0, 1.4) 2,992 80.7 1.1 (1.0, 1.3) 2,564 80.8 0.9 (0.8, 1.1)
Sex at birth
Male 4,123 76.9 <0.0001 Ref 4,229 78.9 0.0007 Ref 3,577 80.4 0.0021 Ref
Female 1,621 81.3 1.1 (0.9, 1.4) 1,644 82.5 1.1 (0.9, 1.3) 1,447 83.8 1.3 (1.0, 1.7)
Raced
Black 4,559 79.8 <0.0001 1.2 (0.9, 1.5) 4,603 80.5 0.0032 1.1 (0.9, 1.4) 3,942 81.5 <0.0001 0.8 (0.6, 1.0)
White 815 75.1 Ref 825 76.0 Ref 730 84.4 Ref
Other/
Unknown
370 66.8 0.6 (0.5, 0.9) 445 80.3 1.2 (0.9, 1.7) 352 74.6 0.5 (0.4, 0.8)
HIV Riske
MSM 2,165 75.1 <0.0001 Ref 2,224 77.2 <0.0001 Ref 1,901 81.8 0.0037 Ref
HRH 1,898 80.2 1.1 (0.9, 1.4) 1,946 82.2 1.2 (1.0, 1.6) 1,700 82.9 1.0 (0.8, 1.3)
IDU 408 81.3 1.2 (0.8, 1.7) 414 82.5 1.3 (0.9, 1.8) 363 80.3 0.9 (0.6, 1.3)
Other 316 87.1 2.2 (1.4, 3.4) 316 87.1 2.1 (1.3, 3.3) 265 82.3 0.9 (0.6, 1.4)
Unknown 957 77.1 1.0 (0.8, 1.2) 973 78.4 1.0 (0.8, 1.2) 795 77.3 0.7 (0.6, 0.9)
Clinic type
Hospital-based 2,682 76.9 0.0224 Ref 2,717 77.9 0.0001 Ref 2,260 81.6 0.6057 Ref
Community-based 3,062 79.1 1.2 (1.0, 1.4) 3,156 81.6 1.3 (1.1, 1.5) 2,764 81.1 1.0 (0.8, 1.2)
aRow percent represents the proportion of participants who met the specific measure out of the population in each demographic group.
bP-value correspond to bivariate comparison of characteristics; P-values less than 0.0083 are considered statistically significant, using a Bonferroni
correction for multiple testing.
cAdjusted odds ratio (aOR) are adjusted for all other variables presented in the table; aORs in bold denote statistical differences at the 0.0083 level, using a
Bonferroni correction for multiple testing.
dOther race includes races reported as Hispanic, Asian, American Indian/Native American, Hawaiian/Other Pacific Islander, White-Black, and Other.
eMSM risk includes persons identified as having both MSM and injection drug use risk. Other risk includes perinatal transmission (65%), transfusion/
coagulation disorder (19%), hemophiliacs and risk due to occupational exposure and other (16%).
Note. IOM = Institute of Medicine; ARV = antiretroviral; OR = odds ratio; CI = confidence interval; MSM = men who have sex with men; HRH = high risk
heterosexual risk; IDU = injection drug use; CBO = community-based organization
https://doi.org/10.1371/journal.pone.0186036.t004
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Measurement of these HHS and IOM quality of care estimates provides a baseline for the
DC Cohort population and a representative snapshot of care delivery in the DC area. Continued
monitoring of these outcomes in the future will allow us to compare groups and track changes
over time. Monitoring of care patterns and clinical outcomes also allows for identification of
disparities in the delivery and achievement of optimal care and opportunities to develop tar-
geted programmatic interventions. Currently, all participating DC Cohort sites receive semi-
annual benchmark reports which include aggregate site-specific data compared to overall
Cohort data as well as lists of out-of-care patients, and patients with detectable viral loads who
may need clinical intervention [10]. While this type of feedback is useful, we are currently devel-
oping more real-time clinical dashboards with select key indicators that providers can access
and review, to allow for better monitoring, screening, and more timely intervention [40]. Mov-
ing forward, by collaborating with the DC DOH and the DC Cohort clinic sites, interventions
may include strengthening patient navigation programs to flag patients in need of screening,
who are at risk of falling out of care, or require other targeted intervention [41].
Our analysis has several limitations worth noting. Our results are only applicable to those
PLWHA who were already linked to care and consented to be in the DC Cohort, thus we are
unable to characterize the first few steps (i.e., HIV testing, linkage to care) of the care contin-
uum. Additionally, our cohort generally represents those in established care; DC Cohort par-
ticipants included in this analysis tended to have relatively high CD4 counts at enrollment
(52%) and almost 60% had never had an AIDS diagnosis. Therefore, this limits our ability to
estimate differences among those who may not be engaged in care and our findings may not
be generalizable to other populations of PLWHA. Moreover, the quality of data depends on
how well data are manually and electronically abstracted through disparate medical record sys-
tems; however, as part of routine DC Cohort data processes, clinical validations and data que-
ries and audits are conducted regularly.
Despite these limitations, our initial assessments of the quality of care being provided in a
large urban area with a high HIV prevalence provide evidence that care delivery among
PLWHA at these participating clinics may be approaching national targets but that disparities
remain at both the individual and clinic level [18]. By using these indicators as baseline mea-
sures of quality of care, we were able to identify gaps in care and, through our unique partner-
ship with the DC DOH and the major HIV providers in the city, we intend to use this
evidence-base to develop strategic and practical public health programs and interventions to
optimize care delivery in Washington, DC.
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